Overview
- Researchers report that semaglutide (Ozempic) can act on rare liver sinusoidal endothelial cells to improve inflammatory liver disease in mice independent of weight loss, and human studies link these drugs to large drops in the blood inflammation marker C‑reactive protein.
- An evidence review finds GLP‑1 therapies drive “quality” weight loss that is mostly fat, with only modest lean mass loss, though experts stress preserving muscle with enough protein and strength training.
- A clinical review for nurse practitioners urges low starting doses with slow titration, close monitoring of labs and symptoms, and clear counseling on common risks like nausea, gallbladder disease, pancreatitis, and delayed stomach emptying.
- Front‑line clinicians warn against starting without lifestyle changes, cutting calories without enough protein, rushing dose increases, or buying drugs online without exams, and they suggest small low‑fat meals, fluids, fiber, and ginger to ease side effects.
- Regulators have already cleared GLP‑1 drugs for kidney and liver disease after diabetes and weight loss use, trials show cardiovascular gains, and companies are testing them for other inflammatory conditions, though the mouse‑based mechanisms still need human proof.